Biotechnology
GenScript Receives "COVID Management Initiative of the Year" in Singapore Business Review Management Excellence Award 2021
SINGAPORE, Dec. 15, 2021 /PRNewswire/ -- GenScript receives the award on COVID Management Initiative of the Year, Biotechnology industry in the Singapore Business Review (SBR) Management Excellence Award 2021. GenScript showed strong commitment and support to global COVID-19 management including ...
2021-12-15 09:26
7358
CellCarta acquires Biogazelle to strengthen its genomic capabilities and expand into digital PCR (dPCR) services
This acquisition solidifies CellCarta's leadership position in genomic services with a unique combination of assay development and global clinical trial sample analysis capabilities covering a comprehensive range of established and cutting-edge genomic technologies. MONTREAL, Dec. 14, 2021 /PRNe...
2021-12-14 20:25
4538
Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital
SINGAPORE and SHANGHAI and BOSTON, Dec. 14, 2021 /PRNewswire/ -- Cargene
Biopharma Inc.
2021-12-14 09:00
5048
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
MINSK, Belarus, Dec. 13, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021. Located in Minsk, capital of the Republic of Belarus and a m...
2021-12-13 22:16
2736
"Finally" User-friendly, Methylcellulose-free Solutions for Meat Substitutes using Citri-Fi® Citrus Fiber
RIVER FALLS, Wis., Dec. 13, 2021 /PRNewswire/ -- Fiberstar, Inc., the leader of high performing citrus fibers, launches new methylcellulose-free solutions to create clean label meat substitutes. "This launch comes at a time when food manufacturers are scrambling for ways to improve meat substitut...
2021-12-13 22:04
4165
Physicians At St. David's Medical Center Among First In Nation To Implant Neurostimulator Technology For Advanced Heart Failure
AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure. The Barostim System is the only technology approved by the Food and Drug Administration ...
2021-12-13 10:08
3257
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors
* ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor * Combination study to begin in H12022 SHANGHAI and HONG KONG, Dec. 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical co...
2021-12-13 08:30
3733
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
5004
Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate * Safety profile was favorable and ...
2021-12-12 09:00
6701
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
MINSK, Belarus, Dec. 10, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021. Located in Minsk, capital of the Republic of Belarus a...
2021-12-10 23:38
5109
Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx
SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...
2021-12-10 15:15
5288
The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization
MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ -- Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...
2021-12-09 21:00
3538
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients
HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...
2021-12-09 20:00
3193
Frost & Sullivan Honors Disruptive Organizations in the Region with Prestigious Industry Awards
16 companies will be recognized at the final Frost & Sullivan Virtual Awards Ceremony of the year, which will be broadcasted live on YouTube at6:00 p.m. (GMT +8),16 December 2021. SINGAPORE, Dec. 9, 2021 /PRNewswire/ -- Frost & Sullivan Best Practices Awards will be honoring 16 leading organizat...
2021-12-09 19:32
2898
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights
2021-12-09 11:24
2893
Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021. This presentation w...
2021-12-08 20:00
3250
China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again
NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...
2021-12-08 18:22
3663
GSK Provides Update on Manufacturing Operations in Singapore
SINGAPORE, Dec. 8, 2021 /PRNewswire/ -- GSK announced today that it will cease manufacturing and outsource all production of amoxicillin that is currently produced at its Quality Road site inSingapore. Amoxicillin is an active pharmaceutical ingredient (API) in GSK's Augmentin product. This will ...
2021-12-08 09:30
4559
Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint
SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemot...
2021-12-08 08:30
3928
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
SUMMARY CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug, and is expected to work on var...
2021-12-07 22:00
3156
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 316 media titles]
2026-05-28 15:06Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 291 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 290 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 285 media titles]
2026-05-28 14:10
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7270
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
7023
